moa of glp-1 agonists receptor (GLP-1RAs): cardiovascular actions and therapeutic potential GLP-1 receptor agonists are Quantity:6 Months sfmc-product-catalog

moa of glp-1 agonists receptor (GLP-1RAs): cardiovascular actions and therapeutic potential GLP-1 receptor agonists are Quantity:6 Months sfmc-product-catalog

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

A recent trial on the treatment effect of semaglutide in people with obesity reported the significant effects of the long-acting GLP-1RA semaglutide on body weight and related phenotypes (169)

sfmc-product-catalog

Quantity:6 Months

Jaisinghani thinks that having the pill will give patients more options and may also reduce the stigma often associated with taking medication for weight loss